SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date earliest event reported) October 21, 1998
-----------------
EMBRYO DEVELOPMENT CORPORATION
------------------------------
(exact name of registrant as specified in its charter)
DELAWARE
--------
(State or other jurisdiction of incorporation)
1-13713 13-3832099
- ---------------------------------------------------------------------
(Commission File Number) (IRS Employer Identification
Number)
750 Lexington Avenue, Suite 2750, New York, NY 10022
- ---------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's Telephone Number, Including Area Code:(212) 355-8484
(Former name or former address, if changed since last
report)
<PAGE>
Item 5. Other Events.
- -----------------------
On October 21, 1998, Embryo Development Corporation (the
"Registrant") was advised by The Nasdaq Stock Market that its securities
were delisted effective with the close of business October 21, 1998 due to
the Company's failure to meet certain continued listing requirements of The
Nasdaq SmallCap Market. Specifically, the Registrant failed to maintain the
required minimum public float, the minimum bid price, and the net tangible
asset requirement.
The Registrant will seek to be eligible to trade on the OTC Bulletin
Board.
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly authorized and caused the
undersigned to sign this Report on the Registrant's behalf.
EMBRYO DEVELOPMENT CORPORATION
By: /s/ Matthew Harriton
---------------------
Matthew Harriton
President
Dated: October 22, 1998
